Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Imv Inc (NQ: IMV )

N/A UNCHANGED
Last Price Updated: 3:58 PM EDT, Apr 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Imv Inc

< Previous 1 2 3 4 5 Next >
Recap: IMV Q4 Earnings
IMV (NASDAQ:IMV) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings IMV... 
Via Benzinga
IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results
From IMV Inc.
Via Business Wire
Earnings Scheduled For March 17, 2022
Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is... 
Via Benzinga
Earnings Preview For IMV
IMV (NASDAQ:IMV) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Earnings Scheduled For November 11, 2021
Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million. • Reshape... 
Via Benzinga
IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform
From IMV Inc.
Via Business Wire
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen... 
Via Benzinga
IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL
From IMV Inc.
Via Business Wire
IMV Inc. to Present at Two Upcoming Investor Events
From IMV Inc.
Via Business Wire
IMV Appoints Andrew Hall as Chief Executive Officer
From IMV Inc.
Via Business Wire
IMV's Basket Clinical Study Shows Promising Top Line Data In Bladder Cancer
IMV Inc (NASDAQ: IMV) announced the finalization of the basket clinical study evaluating maveropepimut-S (MVP-S) in combination with Merck & Co Inc's... 
Via Benzinga
IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts
From IMV Inc.
Via Business Wire
IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility
From IMV Inc.
Via Business Wire
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress
From IMV Inc.
Via Business Wire
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer
From IMV Inc.
Via Business Wire
IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference
From IMV Inc.
Via Business Wire
IMV Inc. Announces Chief Financial Officer to Retire
From IMV Inc.
Via Business Wire
IMV Inc. Announces Third Quarter 2021 Financial and Operational Update
From IMV Inc.
Via Business Wire
Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
From IMV Inc.
Via Business Wire
IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021
From IMV Inc.
Via Business Wire
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
From IMV Inc.
Via Business Wire
Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
From IMV Inc.
Via Business Wire
IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
From IMV Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021
Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE: 
Via Benzinga
IMV Inc. to Present at Three Investor Conferences in September
From IMV Inc.
Via Business Wire
IMV Inc. (IMV) Q2 2021 Earnings Call Transcript
IMV earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.